These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 31819295)
1. Ensuring access to affordable, timely vaccines in emergencies. Elder K; Saitta B; Ducomble T; Alia M; Close R; Scheele S; Erickson E; Scourse R; Kahn P; Elder G Bull World Health Organ; 2019 Dec; 97(12):851-853. PubMed ID: 31819295 [No Abstract] [Full Text] [Related]
2. Are advance market commitments for drugs a real advance? Scudellari M Nat Med; 2011 Feb; 17(2):139. PubMed ID: 21297588 [No Abstract] [Full Text] [Related]
3. The global vaccine enterprise: a developing world perspective. Shin SI Nat Med; 1998 May; 4(5 Suppl):503-5. PubMed ID: 9585198 [No Abstract] [Full Text] [Related]
4. Drugs and vaccines around the world. Health Aff (Millwood); 2006; 25(2):312. PubMed ID: 16522572 [No Abstract] [Full Text] [Related]
5. Is the pneumococcal vaccine Advance Market Commitment motivating innovation and increasing manufacturing capacity? Some preliminary answers. Plahte J Vaccine; 2012 Mar; 30(14):2462-6. PubMed ID: 22300720 [TBL] [Abstract][Full Text] [Related]
6. PneumoADIP: an example of translational research to accelerate pneumococcal vaccination in developing countries. Levine OS; Cherian T; Shah R; Batson A J Health Popul Nutr; 2004 Sep; 22(3):268-74. PubMed ID: 15609779 [TBL] [Abstract][Full Text] [Related]
7. Status of new vaccine introduction – worldwide, September 2016. Wkly Epidemiol Rec; 2017 Jan; 92(1):1-8. PubMed ID: 28058825 [No Abstract] [Full Text] [Related]
8. The global capacity for manufacturing vaccines. Prospects for competition and collaboration among producers in the next decade. Robbins A; Arita I Int J Technol Assess Health Care; 1994; 10(1):39-46. PubMed ID: 8157459 [TBL] [Abstract][Full Text] [Related]
9. Economic perspectives on the advance market commitment for pneumococcal vaccines. Snyder CM; Begor W; Berndt ER Health Aff (Millwood); 2011 Aug; 30(8):1508-17. PubMed ID: 21821567 [TBL] [Abstract][Full Text] [Related]
10. From the World Health Organization. State of the World's Vaccines and Immunizations. JAMA; 2002 Nov; 288(20):2532. PubMed ID: 12444848 [No Abstract] [Full Text] [Related]
11. Vaccines as a global imperative--a business perspective. Stéphenne J Health Aff (Millwood); 2011 Jun; 30(6):1042-8. PubMed ID: 21653955 [TBL] [Abstract][Full Text] [Related]
12. Africa's vaccines revolution must have research at its core. Nature; 2021 Apr; 592(7855):487-488. PubMed ID: 33883739 [No Abstract] [Full Text] [Related]
13. Vaccine candidates for poor nations are going to waste. Kaslow DC; Black S; Bloom DE; Datla M; Salisbury D; Rappuoli R Nature; 2018 Dec; 564(7736):337-339. PubMed ID: 30560957 [No Abstract] [Full Text] [Related]
14. WHO expectation and industry goals. Vandersmissen W Vaccine; 2001 Feb; 19(13-14):1611-5. PubMed ID: 11166883 [TBL] [Abstract][Full Text] [Related]
15. [Improving global access to new vaccines: intellectual property, technology transfer, and regulatory pathways]. Crager SE Rev Panam Salud Publica; 2015 Jan; 37(1):59-68. PubMed ID: 25791189 [TBL] [Abstract][Full Text] [Related]
16. Introducing new vaccines into developing countries: obstacles, opportunities and complexities. Clemens J; Jodar L Nat Med; 2005 Apr; 11(4 Suppl):S12-5. PubMed ID: 15812482 [TBL] [Abstract][Full Text] [Related]
17. Improving access to vaccines through tiered pricing. Berkley S Lancet; 2014 Jun; 383(9936):2265-7. PubMed ID: 24636625 [No Abstract] [Full Text] [Related]
18. New Vaccines for the World's Poorest People. Hotez PJ; Bottazzi ME; Strych U Annu Rev Med; 2016; 67():405-17. PubMed ID: 26356803 [TBL] [Abstract][Full Text] [Related]
19. [Towards a new vaccine economy?]. Poirot P; Martin JF Sante; 1994; 4(3):183-7. PubMed ID: 7921683 [TBL] [Abstract][Full Text] [Related]